Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Last trade$2.98
Day change-$0.22 (-6.88%)
Day range$2.78 – $3.66
Volume77,154
Market cap$55M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$54.97M
Price / earnings
—
Price / book
12.76×
Price / sales
1.81×
EV / sales
1.49×
EV / EBITDA
-1.71×
Profitability
Earnings per share
-$1.82
Return on assets
-86.58%
Return on equity
-724.01%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.32×
Current ratio
1.06×
Quick ratio
0.97×
Cash ratio
0.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.35M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VRCA, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$5.86M
$5.02M
$5.09M
$14.34M
$12.7M
$3.44M
$344K
-$1.78M
Cost of revenue
$878K
$889K
$1.4M
$1.11M
$494K
$437K
$625K
$435K
Gross profit
$4.98M
$4.13M
$3.69M
$13.24M
$12.21M
$3M
-$281K
-$2.22M
Selling, general and administrative
$10.35M
$9.99M
$8.12M
$9.4M
$8.85M
$8.85M
$9.88M
$16.08M
Research and development
$6.03M
$3.86M
$2.52M
$2.21M
$1.85M
$2.28M
$1.17M
$2.41M
Total operating expenses
$18.08M
$13.85M
$10.64M
$11.61M
$10.7M
$11.13M
$11.05M
$18.49M
Operating income
-$13.1M
-$9.72M
-$6.95M
$1.63M
$1.51M
-$8.13M
-$11.33M
-$20.7M
Interest expense
-$164K
-$160K
-$1.31M
-$2.09M
-$2.13M
-$2.2M
-$2.35M
-$2.38M
Income before taxes
-$13.15M
-$9.68M
-$8.07M
-$274K
$204K
-$9.74M
-$16.2M
-$22.86M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$13.15M
-$9.68M
-$8.07M
-$274K
$204K
-$9.74M
-$16.2M
-$22.86M
Net income attributable to common shareholders
-$13.15M
-$9.68M
-$8.07M
-$274K
$204K
-$9.74M
-$16.2M
-$22.86M
EBITDA
-$11.38M
-$9.7M
-$6.93M
$1.65M
$1.55M
-$8.08M
-$11.27M
-$20.64M
Basic earnings per share
-$0.62
-$0.45
-$0.57
-$0.03
$0.02
-$1.03
-$2.40
-$4.88
Diluted earnings per share
-$0.62
-$0.45
-$0.57
-$0.03
$0.02
-$1.03
-$2.40
-$4.88
Recent news
Company coverage with links to the original publishers.
Verrica Pharmaceuticals announced the first patient dosing in a global Phase 3 clinical trial for YCANTH (VP-102) to treat common warts, a condition affecting approximately 22 million patients in the U.S. with no FDA-approved prescription therapies. The Phase 3 program is based on positive Phase 2 COVE-1 results showing 51% complete clearance of warts. Torii will fund approximately 90% of trial costs on a 50/50 cost-sharing basis, with Verrica's portion covered by future milestones and royalties from Japan.
Verrica Pharmaceuticals reported strong Q2 2025 financial results, with non-GAAP EPS of $0.25 and GAAP revenue of $12.7 million, significantly exceeding analyst expectations. The company saw improved performance driven by YCANTH product sales and a major milestone payment from Torii Pharmaceutical.
Verrica Pharmaceuticals announced the acceptance of two abstracts featuring positive preliminary results from a Phase 2 study of its investigational therapy VP-315 for the treatment of basal cell carcinoma. The data showed promising safety, tolerability, and antitumor efficacy.
Verrica Pharmaceuticals reported Q2 2024 financial results, including $4.9M in YCANTH revenue and positive preliminary results from a Phase 2 study of VP-315 for basal cell carcinoma. The company also announced progress in its common warts program and expansion of YCANTH distribution.